Crohn’s Disease
Crohn’s disease is a chronic inflammatory bowel disease characterised by segmental, transmural inflammation that can affect any part of the gastrointestinal tract from mouth to anus. Unlike ulcerative colitis, Crohn’s disease involves the full thickness of the bowel wall, leading to progressive structural damage rather than surface-limited injury.
What You Need to Know
Crohn’s disease is a chronic inflammatory condition that develops when immune tolerance to intestinal contents is lost, leading to persistent and dysregulated immune activation. Unlike ulcerative colitis, inflammation in Crohn’s disease is patchy, with segments of inflamed bowel separated by relatively normal tissue. This pattern reflects focal immune activation rather than continuous surface involvement and contributes to the variable and unpredictable nature of disease presentation.
A defining feature of Crohn’s disease is transmural inflammation, meaning the inflammatory process extends through the full thickness of the bowel wall. This depth of involvement disrupts more than mucosal absorption alone. Blood vessels, lymphatics, nerves, and smooth muscle layers are all affected, altering perfusion, drainage, motility, and structural integrity. As a result, Crohn’s disease produces both local intestinal damage and broader physiological consequences that evolve over time.
Several key mechanisms explain the clinical behaviour of Crohn’s disease:
patchy, segmental inflammation resulting in areas of diseased and spared bowel
full-thickness bowel wall involvement affecting absorption, motility, and tissue strength
ongoing immune activation that promotes progressive structural damage rather than isolated flares
Because inflammation penetrates deeply and healing often occurs through fibrosis rather than restoration of normal architecture, disease progression is driven by cumulative injury. Even when symptoms fluctuate, structural changes such as strictures, fistulae, and impaired nutrient absorption may continue to develop. Crohn’s disease is therefore characterised by both inflammatory activity and progressive tissue damage, with long-term impact determined by the depth and persistence of immune-mediated injury rather than symptom severity alone.
Beyond the Basics
Segmental and patchy immune activation
In Crohn’s disease, immune activation occurs in a discontinuous pattern, producing inflamed segments separated by relatively normal bowel, commonly referred to as skip lesions. This distribution reflects focal loss of immune tolerance rather than widespread mucosal dysregulation. Immune responses are triggered in specific regions, while adjacent tissue may remain structurally and functionally preserved.
This patchy involvement complicates clinical assessment because symptom severity does not always align with the extent or location of inflammation. Areas of active disease may be clinically silent, while symptoms can arise from secondary effects such as obstruction or altered motility in nearby segments.
Transmural inflammation and full-thickness injury
The defining pathological feature of Crohn’s disease is transmural inflammation, where immune-mediated injury extends through the full thickness of the bowel wall. Inflammation involves not only the mucosa but also the submucosa, muscularis propria, and serosa. This depth of involvement distinguishes Crohn’s disease from surface-limited inflammatory conditions.
As inflammation penetrates deeper layers, it disrupts vascular supply, lymphatic drainage, neural signalling, and smooth muscle function. These effects explain why Crohn’s disease produces complications beyond the intestinal lumen, including strictures, fistulae, and extra-intestinal inflammatory manifestations.
Lymphatic obstruction and oedema
Transmural inflammation interferes with lymphatic drainage within the bowel wall. Impaired lymphatic flow leads to accumulation of interstitial fluid, contributing to bowel wall oedema and thickening. Oedematous bowel becomes less compliant and more prone to functional narrowing. This swelling can intermittently reduce luminal diameter and impair motility, producing abdominal pain, bloating, and episodic obstructive symptoms even before fixed structural narrowing has developed. These changes may fluctuate with inflammatory activity.
Fibrosis and stricture formation
Repeated cycles of inflammation followed by incomplete healing stimulate fibroblast activation and collagen deposition within the bowel wall. Over time, this fibrotic response leads to permanent thickening and narrowing of the intestinal lumen.
Fibrotic strictures reflect irreversible architectural change rather than active inflammation. As a result, they do not respond to anti-inflammatory therapy and are a major driver of progressive obstructive symptoms in longstanding disease. This transition from inflammatory to fibrostenotic disease represents cumulative tissue injury rather than disease escalation at a single time point.
Fistulae and sinus tract development
Deep ulceration combined with transmural inflammation weakens the integrity of the bowel wall. When inflammation extends beyond the serosa, abnormal tracts may form between the bowel and adjacent organs, skin, or other bowel segments. Fistulae represent pathological attempts at drainage rather than effective healing. Their presence reflects failure of tissue containment and repair, often leading to chronic infection, abscess formation, and complex disease behaviour that extends beyond the bowel lumen.
Impaired absorption and nutritional consequences
Crohn’s disease frequently involves the small intestine, where most nutrient absorption occurs. Inflammation damages absorptive surfaces, disrupts brush border enzymes, and interferes with normal digestive processes. When the terminal ileum is affected, absorption of bile acids and vitamin B12 is particularly compromised. Malabsorption contributes to weight loss, fatigue, anaemia, micronutrient deficiency, and impaired wound healing. Nutritional depletion further weakens immune regulation and epithelial repair, reinforcing ongoing disease activity and systemic vulnerability.
Altered motility and pain
Inflammation involving the muscular layer disrupts coordinated peristalsis and normal neuromuscular signalling. This leads to cramping, urgency, and abdominal pain, particularly during periods of active inflammation or partial obstruction. Neuromuscular dysfunction may persist even when inflammatory markers improve, explaining why pain and altered bowel habits can continue during apparent remission. These symptoms reflect structural and functional changes rather than active mucosal inflammation alone.
Systemic immune activation
Inflammatory mediators produced within the gut enter systemic circulation and contribute to extra-intestinal manifestations. Joint inflammation, skin lesions, ocular disease, and hepatobiliary involvement arise from shared immune activation rather than direct spread of bowel pathology. The likelihood of systemic effects increases with the depth, extent, and chronicity of intestinal inflammation, highlighting Crohn’s disease as a systemic immune-mediated condition rather than an isolated gastrointestinal disorder.
Relapsing, progressive disease behaviour
Crohn’s disease commonly follows a relapsing course, but structural damage accumulates over time. Each inflammatory episode leaves residual tissue injury, even when symptoms resolve. Healing often occurs through fibrosis rather than restoration of normal architecture. This cumulative damage explains why disease behaviour may evolve from predominantly inflammatory to stricturing or fistulising patterns. Early disease control therefore aims to limit long-term architectural injury and preserve bowel function, rather than focusing solely on short-term symptom suppression.
Clinical Connections
Crohn’s disease presents with a wide range of symptoms that fluctuate over time, reflecting the segmental and transmural nature of inflammation. Abdominal pain, diarrhoea, weight loss, and fatigue may arise from active mucosal inflammation, intermittent obstruction from oedema or strictures, impaired absorption in the small intestine, or systemic immune activation. Because symptoms can originate from different mechanisms, their severity does not always correlate with the degree of active inflammation at any single site.
Several recurring clinical patterns reflect the underlying pathophysiology:
abdominal pain and bloating related to transmural inflammation, altered motility, or partial obstruction
diarrhoea driven by mucosal inflammation, bile acid malabsorption, or reduced absorptive surface
fatigue and weight loss resulting from chronic inflammation, malabsorption, and increased metabolic demand
Management is therefore directed at controlling immune activation while preserving bowel structure and function. Suppressing inflammation reduces ongoing tissue injury, but equal emphasis is placed on preventing fibrotic strictures, fistula formation, and cumulative architectural damage that cannot be reversed once established. Nutritional support is integral to care, as malabsorption and reduced intake weaken immune regulation and impair tissue repair, further perpetuating disease activity.
Long-term outcomes in Crohn’s disease depend on limiting cumulative injury rather than responding to individual flares in isolation. Even when symptoms improve, subclinical inflammation and structural damage may continue to progress. Sustained disease control aims to maintain bowel integrity, reduce systemic inflammatory burden, and prevent complications that drive disability and surgical intervention over time.
Concept Check
Why does transmural inflammation lead to complications not seen in ulcerative colitis?
How do skip lesions complicate diagnosis and monitoring of Crohn’s disease?
Why do fibrotic strictures fail to respond to anti-inflammatory treatment?
How does small bowel involvement contribute to systemic symptoms?
Why does Crohn’s disease often progress despite periods of remission?